UA118542C2 - Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 - Google Patents

Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197

Info

Publication number
UA118542C2
UA118542C2 UAA201412809A UAA201412809A UA118542C2 UA 118542 C2 UA118542 C2 UA 118542C2 UA A201412809 A UAA201412809 A UA A201412809A UA A201412809 A UAA201412809 A UA A201412809A UA 118542 C2 UA118542 C2 UA 118542C2
Authority
UA
Ukraine
Prior art keywords
carrier protein
hiv
peptide coupled
immunogenic compounds
crm197 carrier
Prior art date
Application number
UAA201412809A
Other languages
English (en)
Inventor
Жоель Крузе
Тсон Фан Рафаель Хо
Домінік Дефонтен
Original Assignee
Іннавірвакс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Іннавірвакс filed Critical Іннавірвакс
Publication of UA118542C2 publication Critical patent/UA118542C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Винахід стосується імуногенної сполуки, що включає пептид GP41, ковалентно зв'язаний з білком-носієм, таким як білок CRM197, композиції, що містить вказану імуногенну сполуку, і застосування даної імуногенної сполуки і композиції для попередження і/або лікування стану, що викликаний інфікуванням індивідуума вірусом ВІЛ.
UAA201412809A 2012-05-31 2013-05-30 Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 UA118542C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (1)

Publication Number Publication Date
UA118542C2 true UA118542C2 (uk) 2019-02-11

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201412809A UA118542C2 (uk) 2012-05-31 2013-05-30 Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197

Country Status (21)

Country Link
US (1) US9511136B2 (uk)
EP (2) EP2668959B1 (uk)
JP (1) JP6352251B2 (uk)
KR (1) KR102077876B1 (uk)
CN (1) CN104507496B (uk)
AU (1) AU2013269120B2 (uk)
BR (1) BR112014029861B1 (uk)
CA (1) CA2875162C (uk)
DK (1) DK2668959T3 (uk)
EA (1) EA027803B1 (uk)
ES (2) ES2528109T3 (uk)
HR (1) HRP20150058T1 (uk)
IN (1) IN2014DN10128A (uk)
MX (1) MX360206B (uk)
PL (1) PL2668959T3 (uk)
PT (1) PT2668959E (uk)
RS (1) RS53769B1 (uk)
SI (1) SI2668959T1 (uk)
UA (1) UA118542C2 (uk)
WO (1) WO2013179262A1 (uk)
ZA (1) ZA201409023B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
AU2016250289B2 (en) * 2015-04-17 2017-03-02 Biolife Science Qld Limited A vaccine composition and uses thereof
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
AR047062A1 (es) * 2003-12-17 2006-01-04 Wyeth Corp Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
CA2735278A1 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
BR112014029861B1 (pt) 2022-05-24
EP2668959A1 (en) 2013-12-04
DK2668959T3 (en) 2015-01-26
MX2014014526A (es) 2015-06-02
HRP20150058T1 (hr) 2015-04-10
CN104507496B (zh) 2018-08-03
AU2013269120B2 (en) 2017-04-20
JP2015519359A (ja) 2015-07-09
ES2701084T3 (es) 2019-02-20
BR112014029861A2 (pt) 2017-07-25
PL2668959T3 (pl) 2015-04-30
MX360206B (es) 2018-10-24
WO2013179262A1 (en) 2013-12-05
CN104507496A (zh) 2015-04-08
IN2014DN10128A (uk) 2015-08-21
EA201491969A1 (ru) 2015-04-30
US20150147348A1 (en) 2015-05-28
EP2668959B1 (en) 2014-11-05
EP2854846A1 (en) 2015-04-08
RS53769B1 (en) 2015-06-30
ES2528109T3 (es) 2015-02-04
JP6352251B2 (ja) 2018-07-04
ZA201409023B (en) 2016-08-31
KR20150032266A (ko) 2015-03-25
US9511136B2 (en) 2016-12-06
EP2854846B1 (en) 2018-09-12
CA2875162A1 (en) 2013-12-05
CA2875162C (en) 2021-09-14
PT2668959E (pt) 2015-02-05
KR102077876B1 (ko) 2020-02-14
AU2013269120A1 (en) 2014-12-18
SI2668959T1 (sl) 2015-03-31
EA027803B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201591457A1 (ru) Терапевтические соединения
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
EP3607950A3 (en) Hepatitis b core protein allosteric modulators
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA201390538A1 (ru) Противовирусные соединения
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
EA201890236A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
NZ703064A (en) Inhibitors of hepatitis c virus
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
EA201290956A1 (ru) Вакцина против вич
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич